| |
 |
| |
When in 1995 year laboratory started working at it productivity of Aspergillus terreus strain was about 10 mg/L. Combined mutagenesis included chemical and ultraviolet irradiation treatment allowed to obtain fist line of mutants. Standard agar-based screening was used to identify most prospective mutants. First mutant with a 110-fold increase of productivity was obtained 12 months later as well as media optimization took 4 months for shaken flasks. At present our best mutant produces up to 17 G/L of product and technology is optimized both in shaken flasks and lab scale fermentors.
Patent RU 2261901 C2, priority date 17.10.2003
Dzhavakhiya V., Voinova T., Vavilova N., Santsevich N., Vinokurova N., Kadomtseva V., Dzhavakhiya V., Mishin A.
The strain 44-62 of fungus Aspergillus terreus – producer of Lovastatin, industrial method of isolation of Lovastatin and method of statins’ lactonization.
|
|
|
 |
| |
Lovastatin represents the first of a new class of cholesterol-lowering agents, the HMG-CoA reductase inhibitors, which are indicated for the treatment of primary hypercholesterolaemia. It is a fungal metabolite that was originally isolated from cultures of Monascus ruber and Aspergillus terreus. Lovastatin was also the first HMG-CoA reductase inhibitor acknowledged to slow coronary arteriosclerosis. Lovastatin was purposely developed as a pro-drug to concentrate active drug in the liver during first-pass circulation. Lovastatin was approved by the FDA for the treatment of hypercholesterolaemia in August 1987.
|
|
![](http://".SERVER_NAME."/images/clearpixel.gif){kind=tracking}
